Skip to content
Radiation Lab
Y-90 half-life, beta range, bremsstrahlung

Yttrium-90

Y-90 · Yttrium, Z = 39, A = 90

Yttrium-90 (Y-90) carries 2.01e+16 Bq/g, or 5.44e+5 Ci/g: a gigabecquerel is 49.7 ng, no weighable quantity at all. It decays by beta-minus emission with a half-life of 64.05 hours, which leaves 16.23% of today's activity after a week and 5.4e-9% after three months.

All 3 recorded photon lines sit below the 20 keV cutoff, so Γ is zero by convention and no external dose rate is quoted. The strongest line is 15.78 keV, at 0.00414% emission probability. The recorded spectrum runs 15.7 to 17.8 keV and carries 0.00751% emission probability in all.

The beta endpoint is 2.28 MeV, mean 0.932 MeV over 2 branches. That endpoint stops in 9.20 mm of acrylic or 4.38 mm of glass. Of the beta energy, 0.52% turns into X-rays in acrylic and 6.54% in lead.

Y-90 microspheres and verification of delivered activity

Y-90 delivers therapeutic beta radiation from microspheres placed in the arterial supply of liver tumours. Glass and resin products carry the isotope in different physical forms, so they are not interchangeable preparations simply because they contain the same radionuclide. For glass microspheres, the radioactive yttrium is incorporated into the glass matrix; resin microspheres bind it to their surface. Product choice therefore carries its own preparation, administration and activity measurement procedures alongside the shared decay physics.

Most Y-90 decays reach stable Zr-90 directly. The beta particles deposit energy near the microspheres, while their slowing in matter also generates bremsstrahlung. The FDA-hosted TheraSphere instructions describe an acrylic shield surrounding the dose vial and an outer lead pot: the plastic stops beta particles and the lead reduces exposure to the secondary X-rays. The same instructions warn that residual microspheres in equipment after treatment still require beta shielding and contamination precautions. A completed administration does not mean that all activity has left the delivery apparatus.

Treatment planning examines where arterial delivery is likely to carry the spheres. The TheraSphere instructions use Tc-99m macroaggregated albumin imaging to assess perfusion and potential passage towards the lungs or gastrointestinal tract. Its labelled indication addresses selected patients with unresectable hepatocellular carcinoma, rather than every liver tumour. Planned distribution and delivered distribution can differ, however. The AAPM guideline identifies differences between the planning particles and treatment spheres, changes in catheter position and vascular conditions as reasons to check the actual outcome of delivery.

Post-treatment imaging can use the continuous bremsstrahlung spectrum for SPECT or a rare internal pair-production branch for PET. That PET signal does not make Y-90 a conventional beta-plus emitter. Quantitative reconstruction requires appropriate corrections, particularly for scatter in SPECT and random coincidences and dead time in PET. AAPM recommends verifying scanner performance rather than assuming a familiar imaging protocol remains quantitative for Y-90. Residual activity measurements also contribute to establishing the administered amount. Together these observations separate activity ordered, activity delivered and activity retained in particular tissues, which are related quantities but answer different dosimetry questions.

Half-life, specific activity and beta endpoint

Half-life64.05 hours (2.67 days; 2.306e+5 s)
Decay modebeta-minus decay
Specific activity2.01e+16 Bq/g (5.44e+5 Ci/g)
Beta endpoint / mean2.28 MeV / 0.932 MeV

9.20 mm of acrylic stops the 2.28 MeV endpoint

Katz–Penfold fit to the 2.28 MeV endpoint — a stopping thickness rather than an attenuation length. Why the material matters more than the thickness.

AbsorberRange for the endpoint (mm)
acrylic9.20
aluminum4.06
water10.9
glass4.38
Shield materialFraction of beta energy converted to X-rays
acrylic (Z ≈ 6.5)0.52%
lead (Z = 82)6.54%

Activity over days and weeks

Ten half-lives is 26.7 days — for Y-90 itself, a storage problem rather than a disposal one, since those ten half-lives already take it below 0.1% of today's activity. The mean life 1/λ is 3.85 days.

ElapsedFraction remaining
1 half-life50.0 %
2 half-lives25.0 %
5 half-lives3.13 %
10 half-lives0.0977 %
Time to fall to 10 % of today's activity8.87 days
Time to fall to 1 %17.7 days
Time to fall to 0.1 %26.6 days

Limits of these range figures

Beta and decay calculators for Y-90

Other Yttrium nuclides: Y-88, Y-88m1, Y-88m2, Y-90m, Y-91

Computed from the IAEA Nuclear Data Section — Livechart API (ENSDF) and the NIST X-Ray Mass Attenuation Coefficients. Derivations and citations.